CHE

Business Context and Reporting Period

Company: Chemed Corporation (CHE)

Filing Type: Form 10-Q (Unaudited)

Reporting Period: Quarter and nine months ended September 30, 2024

Chemed operates through two primary segments: VITAS Healthcare (hospice care) and Roto-Rooter (plumbing, drain cleaning, and water restoration). The company reported strong growth in the VITAS segment driven by increased days of care and Medicare reimbursement rates, while the Roto-Rooter segment experienced a decline in revenue across all service lines.

Key Financial Metrics

Margins: Consolidated gross margin was 34.6% for both Q3 and the nine months ended September 30, 2024. Adjusted EBITDA margin was 20.3% for Q3 2024 and 20.0% for the nine-month period.

Material Changes vs. Prior Period

• Revenue Growth: Consolidated revenue increased 7.4% in Q3 and 6.7% for the nine months. This was driven by a 17.3% increase in VITAS revenue (due to a 15.5% increase in days of care and a 2.6% Medicare rate increase) offset by a 6.9% decline in Roto-Rooter revenue (due to lower job counts across all service lines).
• Profitability: Net income increased 1.1% in Q3 and 16.0% for the nine months. VITAS after-tax earnings increased significantly, while Roto-Rooter earnings declined due to lower revenue and higher marketing expenses.
• Acquisitions: On April 17, 2024, VITAS acquired Covenant Care for $85.0 million. This contributed approximately $10.0–$11.0 million in revenue and $1.8–$2.0 million in net income for Q3 2024.
• Balance Sheet: Goodwill increased by $81.8 million primarily due to the Covenant acquisition. Cash and cash equivalents decreased by $25.5 million year-to-date, largely due to $152.0 million in treasury stock repurchases and $97.4 million in business combination costs.

Guidance, Outlook, and Risks

• Full-Year 2024 Guidance: Management estimates full-year 2024 adjusted diluted EPS in the range of $23.00 to $23.15. This represents a 13.3% to 14.0% increase over the prior year's reported adjusted EPS of $20.30. The guidance assumes a 24.3% effective tax rate and 15.22 million diluted shares.
• Operational Outlook:
  • VITAS: Performance remains on track. Hurricane Helene caused a temporary slowdown in admissions (estimated 60–100 patients) in Q3, with potential further impact in Q4 due to Hurricane Milton.
  • Roto-Rooter: Revenue and adjusted EBITDA were softer than anticipated in Q3.
• Risks and Contingencies:
  • Regulatory: VITAS is subject to a Medicare audit (OAS) regarding elevated levels of care. A demand letter sought repayment of $50.3 million; VITAS has deposited this amount under appeal and believes the audit methodology is flawed.
  • Special Focus Program (SFP): CMS may select VITAS locations for the SFP, which could impact brand reputation and increase compliance costs, though no direct fines are imposed.
  • Concentration: Approximately 83% of consolidated accounts receivable are from Medicare, Medicaid, and managed Medicaid programs.

Investor Verification Checklist

• Acquisition Integration: Verify the financial contribution and integration progress of the Covenant Care acquisition ($85M purchase price).
• Roto-Rooter Turnaround: Monitor job count trends and the effectiveness of increased marketing spend in reversing the revenue decline.
• Regulatory Exposure: Track the status of the $50.3 million Medicare audit appeal and potential impacts from the CMS Special Focus Program selection.
• Cash Utilization: Review the pace of share repurchases ($145.9M YTD) against the remaining authorization ($168.1M) and liquidity needs.
• Seasonality/Weather Impact: Assess the actual Q4 impact of Hurricanes Helene and Milton on VITAS admissions and Roto-Rooter water restoration demand.